Baudax Bio (BXRX) Stock Analysis

What Baudax Bio does

Baudax Bio, Inc. is a pharmaceutical enterprise dedicated to creating and marketing therapeutic solutions for inpatient and urgent care environments. Their flagship commercial offering is ANJESO, an injectable meloxicam formulation designed to alleviate moderate to severe pain, which can be administered independently or in conjunction with non-NSAID pain medications. The company's research and development portfolio features several candidates: BX1000, an intermediate-acting neuromuscular blocker currently in Phase II trials; BX2000, an ultra-short-acting variant of the same class, undergoing Phase I investigation; BX3000, an agent intended to reverse neuromuscular blockade; and Dex-IN, a unique intranasal delivery system for dexmedetomidine. Founded in 2019, the firm operates from its base in Malvern, Pennsylvania.

Key metrics

ETFs linked to BXRX

Broad-market and Healthcare sector ETFs an investor holding Baudax Bio is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how BXRX fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Baudax Bio?

Baudax Bio trades under the ticker BXRX on NASDAQ.

Which exchange is BXRX listed on?

BXRX is listed on NASDAQ.

What sector does Baudax Bio operate in?

Baudax Bio is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze BXRX in a portfolio?

PortView shows BXRX's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.